Activation of epitope-specific memory cytotoxic T lymphocyte responses by synthetic peptides

Clinical and Experimental Immunology

Volumn 105, Issue 2, 1996, Pages 369-375

  Reali, E ^a   Guerrini, R ^a   Giori, B ^a   Borghi, M ^a   Marastoni, M ^a   Tomatis, R ^a   Traniello, S ^a   Masucci, M G ^b   Gavioli, R ^a,c  

^a UNIVERSITY OF FERRARA   (Italy)

^b KAROLINSKA INSTITUTE   (Sweden)

^c Dipto di Biochim e Biol Molec   (Italy)

Author keywords

Cytotoxic T lymphocytes; Epstein Barr virus; HLA A11; Immunogenic peptides

Indexed keywords

HLA ANTIGEN; SYNTHETIC PEPTIDE;

ARTICLE; CYTOTOXIC T LYMPHOCYTE; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; LYMPHOBLASTOID CELL LINE; PRIORITY JOURNAL;

EID: 0030018397     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1996.d01-744.x     Document Type: Article

References (45)

1. Zinkernagel RM, Welsh RM. H-2 compatibility requirement for virus-specific T cell-mediated effector functions in vivo. Specificity of T cells conferring antiviral protection against lymphocytic choriomenengitis virus is associated with H-2K and H-2D. J Immunol 1976; 117:1495-502.
2. Yap KL, Ada GL, Mckenzie IFC. Transfer of specific cytotoxic T lymphocytes protect mice inoculated with influenza virus. Nature (London) 1978; 273:238-40.
3. Taylor PM, Askonas BA. Influenza nucleoprotein-specific cytotoxic T-cell clones are protective in vivo. Immunol 1986; 58:417-20.
4. Romero P, Maryanski JL, Corradin G, Nussenzweig RS, Nussenzweig V, Zavala F. Cloned cytotoxic T cells recognize an epitope in the circumsporozoite protein and protect against malaria. Nature (London) 1989; 341:323-5.
5. Knuth A, Wolfel T, Klehmann E, Boon T, Meyer Zum Buschenfelde KH. Cytolytic T-cell clones against an autologous human melanoma: specificity study and definition of three antigens by immunoselection. Proc Natl Acad Sci USA 1989; 86:2804-8.
6. Coulie PG, Lehmann F, Lethé B, Herman J, Lurquin C, Andrawiss M, Boon T. A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proc Natl Acad Sci USA 1995; 92:7976-80.
7. Townsend ARM, Rothbard J, Gotch FM, Bahadur G, Wraith D, McMichael AJ. The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides. Cell 1986; 44:959-68.
8. Falk K, Rötzschke O, Stevanovic S, Jung G, Rammensee H-G. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature (London) 1991; 351:290-6.
9. Schulz M, Zinkernagel RM, Hengartner H. Peptide-induced antiviral protection by cytotoxic T cells. Proc Natl Acad Sci USA 1991; 88:991-3.
10. Kast WM, Roux L, Curren J, Blom HJJ, Voordouw AC, Meloen R, Kolakowsky D, Melief CJM. Protection against lethal Sendai virus infection by in vivo priming of virus-specific cytotoxic T lymphocytes with free synthetic peptide. Proc Natl Acad Sci USA 1991; 88:2283-7.
11. Feltkamp MCW, Smits HL, Vierboom MPM et al. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol 1993; 23:2242-9.
12. Mukherji B, Chakraborty NG, Yamasaki S et al. Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. Proc Natl Acad Sci USA 1995; 92:8078-82.
13. Melief CJM. Tumor eradication by adoptive transfer of cytotoxic T lymphocytes. Adv Cancer Res 1992; 58: 143-73.
14. Gammon G, Shastri N, Cogswell J, Wilbur S, Sadegh Nasseri S, Krzych U, Miller A, Sercaz E. The choice of T-cell epitopes utilized on a protein antigen depends on multiple factors distant from, as well as at the determinatnt site. Immunol Rev 1987; 98:53-73.
15. Sereaz EE, Lehmann PV, Ametani A, Benichou G, Miller A, Moudgii K. Dominance and crypticity of T cell antigenic determinants. Annu Rev Immunol 1993; 11: 729-66.
16. Pircher H, Moskopidis D, Rohrer U, Bürki K, Hengartner H, Zinkernagel RM. Viral escape by selection of cytotoxic T-cell-resistant virus variants in vivo. Nature (London) 1990; 346:629-31.
17. Phillips RE, Rowland-Jones S, Nixon DF et al. Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition. Nature (London) 1991; 354:453-9.
18. + population. Science 1993; 260:98-100.
19. Bertoletti A, Sette A, Chisari FV, Penna A, Levrero M, De Carli M, Fiaccadori F, Ferrari C. Natural variants of cytotoxic epitopes are T cell receptor antagonists for anti-viral cytotoxic T cells. Nature (London) 1994; 369:407-10.
20. Moskophidis D, Zinkernagel RM. Immunobiology of cytotoxic T-cell escape mutants of lymphocytic choriomenengitis virus. J Virol 1995; 69:2187-93.
21. Klenerman P, Meier U-C, Phillips RE, McMichael AJ, The effects of natural altered peptide ligands on the whole blood cytotoxic T lymphocyte response to human immunodeficiency virus. Eur J Immunol 1995; 25:1927-31.
22. Rickinson AB, Moss DJ, Allen DJ, Wallace LE, Rowe M, Epstein MA. Reactivation of Epstein Barr virus-specific cytotoxic T cells by in vitro stimulation with the autologous lymphoblastoid cell line. Int J Cancer 1981; 27:593-601.
23. Khanna R, Borrows SR, Kurilla MG, Jacob CA, Misko IS, Sculley TB, Kieff E, Moss DJ. Localisation of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development. J Exp Med 1992; 176:169-76.
24. Murray RJ, Kurilla MG, Brooks, JM, Thomas WA, Rowe M, Kieff E, Rickinson AB. Identificiation of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies. J Exp Med 1992; 176:157-68.
25. de Campos-Lima PO, Levitsky V, Brooks J, Lee SP, Hu LF, Rickinson AB, Masucci MG. T cell responses and virus evolution: loss of HLA A11-resticted CTL epitopes in Epstein Barr virus isolates from highly A11-positive populations by selective mutation of anchor residues. J Exp Med 1994; 179:1297-305.
26. Gavioli R, Kurilla M, de Campos-Lima PO, Wallace L, Dolcetti R, Murray RJ, Rickinson AB, Masucci MG. Multiple HLA A11-restricted cytotoxic T-lymphocyte epitopes of different immunogenicities in the Epstein-Barr virus-encoded nuclear antigen 4. J Virol 1993; 67:1572-8.
27. Cerundolo V, Alexander J, Anderson K, Lamb C, McMichael A, Goth F, Townsend A. Presentation of viral antigen controlled by a gene in the major histocompatibility complex. Nature (London) 1990; 345:449-52.
28. Zhang Q-J, Gavioli R, Klein G, Masucci MG. An HLA-A11-specific motif in nonamer peptides derived from viral and cellular proteins. Proc Natl Acad Sci USA 1993; 90:2217-21.
29. Salter R, Cresswell P. Impaired assembly and transport of HLA-A and -B antigens in a mutant T×B cell hybrid. EMBO J 1986; 5:943-9.
30. Miller G, Lipman M. Release of infectious Epstein-Barr virus by transformed marmoset leukocytes. Proc Natl Acad Sci USA 1973; 70:190-4.
31. Gavioli R, Zhang Q-J, Marastoni M, Guerrini R, Reali E, Tomatis R, Masucci MG, Traniello S. Effect of anchor residue modifications on the stability of HLA-A11 peptide complexes. Biochem Biophys Res Commun 1995; 206:8-14.
32. Rabin H, Hopkins RF, Ruscetti FW, Neubawer RH, Brown RL, Kawakami TG. Spontaneous release of a factor with properties of T-cell growth factor from a continuous line of primate tumor T cells. J Immunol 1981; 127:1852-6.
33. Colombani J, Dausset J, Lepage V, Degos L, Kalil J, Fellous M. HLA monoclonal antibody registry: a proposal. Tissue Antigens 1982; 20:161-71.
34. Gavioli R, De Campos-Lima PO, Kurilla MG, Kieff E, Klein G, Masucci MG. Recognition of the EBV encoded nuclear antigens EBNA-4 and EBNA-6 by HLA A11 restricted cytotoxic T-lymphocytes. Implications for the down-regulation of HLA A11 in Burkitt's lymphoma. Proc Natl Acad Sci USA 1992; 89:5862-6.
35. Carbone FR, Moore MW, Sheil JM, Bevan MJ. Induction of cytotoxic T lymphocytes by primary in vitro stimulation with peptides. J Exp Med 1988; 167:1767-79.
36. Houbiers JGA, Nijman HW, van der Burg SH et al. In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53. Eur J Immunol 1993; 23:2072-7.
37. Steinman RM, Young JW. Signals arising from antigen-presenting cells. Curr Opinin Immunol 1991; 3:361-72.
38. Hill AB, Lee SP, Haurum JS et al. Class I major histocompatibility complex-restricted cytoxic T lymphocytes specific for Epstein Barr virus (EBV) nuclear anitgens fail to lyse the EBV-transformed B lymphoblastoid cell lines against which they were raised. J Exp Med 1995; 181:2221-8.
39. Harding CV, Unanue ER. Quantitation of antigen presenting cell MHC class II/peptide complexes necessary for T-cell stimulation. Nature (London) 1990; 346:574-6.
40. Kageyama S, Tsomides TJ, Sykulev Y, Eisen HN. Variations in the number of peptide-MHC class I complexes required to activate cytotoxic T cell responses. J Immunol 1995; 154:567-76.
41. De Bruijn MLH, Nieland JD, Schumacher TNM, Ploegh HL, Kast WM, Melief CJM. Mechanism of induction of primary virus-specific cytotoxic T lymphocyte response. Eur J Immunol 1992; 22:3013-20.
42. van der Burg SH, Klein MR, van de Velde CJH, Kast WM, Miedema F, Melief CJM. Induction of primary human cytotoxic T-lymphocyte response against a novel conserved epitope in a functional sequence of HIV-1 reverse transcriptase. AIDS 1995; 9:121-7.
43. Schmidt C, Burrows SR, Sculley TB, Moss DJ, Misko IS. Non-responsiveness to an immunodominant Epstein-Barr virus-encoded cytotoxic T-lymphocyte epitope in nuclear antigen 3A: implications for vaccine strategies. Proc Natl Acad Sci USA 1991; 88: 9478-82.
44. Eisenlohr LC, Yewdell JW, Bennink JR. Flanking sequences influence the presentation of an endogenously synthesized peptide to cytotoxic T lymphocytes. J Exp Med 1992; 175:481-7.
45. Tussey LG, Rowland-Jones S, Zheng TS, Androlewicz MJ, Cresswell P, Frelinger JA, McMichael AJ. Different MHC class I alleles compete for presentation of overlapping viral epitopes. Immunity 1995; 3:65-77.